Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of HIV-DNA resistance mutations detected by NGS on simplification to 2-drug regimens
2021-000243-50Phase 3Terminated
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lamivudine, doravirine, emtricitabine, dolutegravir + rilpivirine, dolutegravir and 2 more in human immunodeficiency virus infection (HIV), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Virological suppression at 48 weeks. Started Jun 2021; status: terminated.
02
Drugs
lamivudinedoravirineemtricitabinedolutegravir + rilpivirinedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-000243-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000243-50.